



## Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference

May 6, 2024

PHILADELPHIA, May 6, 2024 /PRNewswire/ -- [Carisma Therapeutics Inc.](#) (Nasdaq: [CARM](#)) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13<sup>th</sup> at 12:00 pm ET.

—  
An audio webcast of the event will be available on the Company's [Investor Events](#) section of the Investor Relations webpage and will be archived for a limited time following the event.

### About Carisma

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit [www.carismatx.com](http://www.carismatx.com).

### Investors:

Shveta Dighe  
Head of Investor Relations  
[investors@carismatx.com](mailto:investors@carismatx.com)

### Media Contact:

Julia Stern  
(763) 350-5223  
[jsstern@realchemistry.com](mailto:jsstern@realchemistry.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-citizens-jmp-life-sciences-conference-302135910.html>

SOURCE Carisma Therapeutics Inc.